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ABSTRACT
Background: Hyperthyroidism is a rare disorder which may negatively affect health and quality of life.
Its occurrence in childhood cancer survivors has not previously been investigated in detail.
Material and methods: In the hospital registers of the five Nordic countries, 32,944 childhood cancer
survivors and 212,675 population comparisons were followed for the diagnosis of hyperthyroidism.
Hospitalisation rates, standardised hospitalisation rate ratios and absolute excess risks were calculated
with 95% confidence intervals (CI).
Results: Hyperthyroidism was diagnosed in 131 childhood cancer survivors, yielding an overall relative
risk of 1.6 (95% CI: 1.3–1.9) compared with population comparisons. The risk was greatest 1–5 years
after the diagnosis of cancer and in survivors of thyroid cancers, neuroblastomas, acute lymphoblastic
leukaemia and Hodgkin lymphoma. Sixty-seven percent of survivors with hyperthyroidism had tumours
located in the head, neck or upper body and half of survivors with hyperthyroidism were irradiated
with 77% of them in the head and neck area.
Conclusion: Childhood cancer survivors are at an increased risk of hyperthyroidism, potentially result-
ing in non-endocrine morbidity.
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Introduction
Childhood cancer survivors often have abnormalities of the
thyroid gland. These include the most common, hypothyroid-
ism, but also thyroid carcinomas, autoimmune thyroid disor-
ders and hyperthyroidism [1]. Thyroid complications occur
primarily in patients treated with radiation to the thyroid
gland or the hypothalamic-pituitary axis [2]. Chemotherapy
alone has not been shown to increase the risk of thyroid dys-
function [1], but studies suggest a sensitising effect [3,4]. The
Childhood Cancer Survivor Study (CCSS) and the Adult Life
after Childhood Cancer in Scandinavia (ALiCCS) study both
identified increased risks of hyperthyroidism in childhood
cancer survivors [5–8]. The aim of this study was to look fur-
ther into these findings by obtaining more thorough infor-
mation on those survivors who develop hyperthyroidism
using the population-based ALiCCS cohort large enough to
investigate rarely, but potentially severe late effects. To the
best of our knowledge, this is the first detailed study of
hyperthyroidism in childhood cancer survivors. It will add to
the knowledge on treatment-related risk factors for hyperthy-
roidism, which will be useful for guiding those clinicians
being responsible for long-term follow-up care of survivors
to identify high-risk patients.
Material and methods
As described previously in greater detail [9], the ALiCCS
cohort consists of 43,909 individuals registered with cancer
before 20 years of age in the national cancer registries of
Denmark, Finland, Iceland, Norway and Sweden between the
start of the cancer registries in the 1940s and 1950s and 31
December 2008. The Nordic cancer registries are nationwide
and with virtually 100% coverage [10–13]. From the regis-
tries, we obtained information on the type of cancer and
date of diagnosis, and patients were assigned to the 12 main
diagnostic groups of the International Classification Scheme
for Childhood Cancer with lymphoma further divided into
Hodgkin and Non-Hodgkin lymphomas [14]. Since the start
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of centralised civil registration in the Nordic countries, all res-
idents have been assigned a unique personal identification
number, which allows accurate linkage of information
among registries.
For comparison, we randomly selected 219,131 individuals
of the same sex, age and country in the national population
registries, referred to as population comparisons. Information
on vital status and migration during follow-up was collected
from the population registers for both patients and popula-
tion comparisons.
Before linkage of study subjects to the respective national
hospital registers, we excluded those in whom more than
one primary cancer had been diagnosed in childhood, those
who had died or emigrated before the start of the national
hospital registers, those who had died or were censored dur-
ing the first year after the date of cancer diagnosis or an
equivalent time lag for the comparison subjects, those with
a diagnosis of a chromosome abnormality and those with a
hospital contact for hyperthyroidism before the date of can-
cer diagnosis or the equivalent date for comparisons. These
exclusions resulted in a cohort of 32,944 1-year survivors and
212,675 population comparisons.
The nationwide hospital registers contain information on
virtually all non-psychiatric hospital admissions in the five
countries [15,16]. Using the unique personal identification
number assigned to all citizens of the Nordic countries, we
followed survivors and comparisons in the hospital registers
for a primary or supplementary discharge diagnosis of hyper-
thyroidism (ICD-7: 252, ICD-8: 242, ICD-9: 242 and ICD-10:
E05). We also included hospital-based outpatient visits in
Denmark since 1995 and in Sweden since 2001.
Information on cancer treatment was abstracted from the
medical records of the Danish survivors with hyperthyroidism
(n = 43) diagnosed with cancer in 1970–2008, of which we
received complete records for 28 patients. For 15 patients,
we were unable to collect substantial treatment information
from medical records either because the old records were
lost in the hospitals, destroyed, or did not include complete
information on treatment. To validate the discharge diagno-
sis of hyperthyroidism, we obtained information on prescrip-
tions for thyroid and anti-thyroid hormones in 1995–2010
from the Danish Prescription Register for a sub-cohort of 34
Danish childhood cancer survivors with hyperthyroidism.
Anti-thyroid medication included all pharmaceutical groups
within ATC code H03B; i.e., thiouracils, sulfur-containing imid-
azole derivatives, perchlorates and other anti-thyroid prepa-
rations. Thyroid medications included prescriptions with all
thyroid preparations (ATC code H03B).
Statistical analysis
Follow-up for hyperthyroidism began one year after the date
of cancer diagnosis (and the corresponding date for popula-
tion comparisons) or at the start of the hospital registers,
whichever occurred first. We compared the number of first
hospital contacts with hyperthyroidism in childhood cancer
survivors with the expected numbers derived from the
appropriate country, sex, age and calender-period specific
hospitalisation rates of the population comparisons.
Hospitalisation rates and standardised hospitalisation rate
ratios (RRs) were calculated with 95% confidence intervals
(CIs). Absolute excess risks (AERs) were derived as the differ-
ence between observed and expected rates of hospitalisation
of survivors per 100,000 person-years, with corresponding
95% CIs.
Results
The 32,944 1-year survivors of childhood cancer were fol-
lowed in the national hospital registers for 435,103 person-
years, during which time 131 survivors had at least one hos-
pital contact for hyperthyroidism; as 83 would have been
expected, the RR was 1.57 (95% CI: 1.30–1.90), and the over-
all AER was 11 (6–16) per 100,000 person-years (Table 1).
Thus, following 1,000 survivors for a decade would result in
one new excess hospital contact with hyperthyroidism.
The RR was 1.4 for women (95% CI: 1.2–1.8) and 2.3 for
men (95% CI: 1.6–3.4), which resulted in an AER of 14 (4–23)
per 100,000 person-years for women and 8 (3–13) per
100,000 person-years for men. The highest risks for hyperthy-
roidism were those of survivors of thyroid cancer (RR =3.9;
95% CI: 2.4–6.4), neuroblastoma (RR =2.4; 95% CI: 1.0–5.8),
Hodgkin lymphoma (RR =2.4; 95% CI: 1.4–4.0) and acute
lymphoblastic leukaemia (ALL) (RR =2.3; 95% CI: 1.4–3.8). Of
the 131 survivors who developed hyperthyroidism, 91 had
had a solid tumour in childhood. Topographic information
from the cancer registries showed that 67% of these survi-
vors had tumours located in the head, neck or upper body,
22% in the mid- and lower body and 8% in the extremities;
3% were of unknown topography. The risk for hyperthyroid-
ism was highest 1–5 years after diagnosis of childhood can-
cer (RR =5.5; 95% CI: 3.5–8.6) (Table 1). In survivors of ALL,
central nervous system (CNS) tumours and thyroid carcin-
oma, the risk was also highest in the first years after the can-
cer diagnosis, whereas the risk of survivors of Hodgkin
lymphoma was highest 5–9 years and 10–19 years after diag-
nosis (Table 2).
Of the 28 Danish survivors with hyperthyroidism for
whom information on cancer treatment was available, 25
had undergone surgery, and all six survivors of thyroid can-
cer had undergone partial or full thyroidectomy (Table 3).
Ten of the 13 survivors (77%) who received radiotherapy
were irradiated in the head-and-neck area, and five survivors
were treated in multiple areas for metastatic cancer. The
radiation doses ranged from 12.5 Gy to 74 Gy, with a median
total dose of 46.4 Gy to the head, neck and upper body
(data not shown).
In the Danish Prescription Register, we found that 30 of
34 patients with a hospital contact for hyperthyroidism in
the Danish Hospital Register were also prescribed anti-thy-
roid drugs, confirming the diagnosis of hyperthyroidism.
Discussion
Overall, one-year survivors of childhood cancer were found
to be at a 1.6-fold increase in risk for hyperthyroidism,
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compared with population comparison subjects. The highest
risks were seen 1–5 years after cancer treatment and in survi-
vors of thyroid cancers, neuroblastomas, ALL and Hodgkin
lymphoma. Both the distribution of malignancies among sur-
vivors with hyperthyroidism and the received cancer treat-
ment, suggest that hyperthyroidism occurs as a result of
damage to the thyroid gland and/or the hypothalamic-pituit-
ary axis.
The increased risk of survivors of childhood cancer for
hyperthyroidism has been addressed in only a few studies.
Most reported a few cases of hyperthyroidism, without fur-
ther details [17–19]. However, three CCSS studies have com-
pared the risk of hyperthyroidism in childhood cancer
survivors to that of their siblings [6–8]. The results were simi-
lar to ours for childhood cancer survivors overall (1.6 in our
study, 2.5 in CCSS based on 290 cases) and for survivors of
ALL (2.3 in our study, 2.0 in CCSS) [7,8], but there was a strik-
ing difference in the results for survivors of Hodgkin lymph-
oma (2.4 in our study, 8.0 in CCSS), which may reflect
differences in radiation practice [6,20]. All three CCSS studies
showed that hyperthyroidism was associated with radiother-
apy. For childhood cancer survivors overall, the risk for
hyperthyroidism increased with the total irradiation dose [8].
For survivors of Hodgkin lymphoma, those treated with
≥35 Gy to the thyroid gland were at highest risk [6]; for survi-
vors of ALL, those treated with craniospinal irradiation or
≥20 Gy to the pituitary gland combined with ≥15 Gy to the
thyroid gland were at higher risk for hyperthyroidism than
survivors treated with chemotherapy only [7]. Autoimmune
thyroid disorders leading to hyperthyroidism have been
reported in childhood cancer survivors undergoing stem-cell
transplantation, probably due to adoptive transfer of abnor-
mal clones of T or B cells from donor to the patient [21–23].
This study is the first comprehensive study on hyperthy-
roidism after childhood cancer. It included all Nordic child-
hood cancer survivors and all types of cancers and is based
on medically verified diagnoses of hyperthyroidism regis-
tered by treating physicians. Further strengths include







AERa (95% CI)Observed Expected Observed Expected
Total 32 944 131 83.3 1.57 (1.30–1.90) 30.2 19.2 11 (6–16)
Sex
Female 15 348 98 68.9 1.4 (1.2–1.8) 47.3 33.2 14 (4–24)
Male 17 596 33 14.5 2.3 (1.6–3.4) 14.5 6.4 8 (3–13)
Age at cancer diagnosis (years)
0–4 10 029 23 16.2 1.4 (0.9–2.2) 17.3 12.1 5 (–2 to 12)
5–9 5 827 19 11.7 1.6 (1.0–2.6) 25.3 15.6 10 (–2 to 21)
10–14 6 450 27 18.8 1.4 (1.0–2.1) 31.3 21.9 9 (–2 to 21)
15–19 10 638 62 36.6 1.7 (1.3–2.2) 44.4 26.2 18 (7–29)
Time since cancer diagnosis (years)
1–5 24 982 22 4.0 5.5 (3.5–8.6) 27.2 4.9 22 (11–34)
6–9 20 637 19 7.6 2.5 (1.6–4.0) 22.5 9.0 13 (3–24)
10–19 18 475 34 22.4 1.5 (1.1–2.1) 26.5 17.5 9 (0–18)
≥20 13 988 56 49.3 1.1 (0.9–1.5) 39.9 35.1 5 (–6 to 15)
Age at hospital contact with hyperthyroidism (attained age)
0–9 11 510 7 0.2 47.3 (5.9–381.0) 15.7 0.3 15 (4–27)
10–19 21 630 14 6.2 2.3 (1.2–4.1) 13.0 5.8 7 (0–14)
20–29 19 072 46 22.2 2.1 (1.5–2.9] 35.8 17.2 19 (8–29)
30–39 12 265 26 23.7 1.1 (0.7–1.7) 31.8 28.9 3 (–10 to 16)
40–49 6 972 11 14.8 0.7 (0.4–1.4) 24.6 33.2 –9 (–24 to 7)
50–59 3 348 19 10.8 1.8 (1.1–2.9) 93.5 52.3 41 (–3 to 84)
≥60 1 313 8 5.7 1.4 (0.7–3.0) 118.8 84.0 35 (–52 to 122)
Type of cancer
Leukaemia (all combined) 6 926 21 8.8 2.4 (1.6–3.7) 29.5 12.3 17 (5–30)
ALL 5 568 16 6.9 2.3 (1.4–3.8) 26.8 11.6 15 (2–28)
Lymphoma 4 504 19 10.3 1.9 (1.2–2.9) 31.8 17.2 15 (0–29)
Hodgkin lymphoma 2 453 15 6.3 2.4 (1.4–4.0) 46.5 19.4 27 (4–51)
Non-Hodgkin lymphoma 1 803 4 3.5 1.1 (0.4–3.1) 16.8 14.8 2 (–14 to 19)
CNS tumours 7 922 30 21.0 1.4 (1.0–2.1) 27.8 19.5 8 (–2 to 18)
Neuroblastomas 1 318 5 2.1 2.4 (1.0–5.8) 30.9 12.8 18 (–9 to 45)
Retinoblastomas 822 2 2.8 0.7 (0.2–2.9) 12.6 17.8 –5 (–23 to 12)
Renal tumours 1 409 2 3.1 0.6 (0.2–2.6) 9.1 14.0 –5 (–18 to 8)
Hepatic tumours 241 0 0.2 NA NA NA NA
Malignant bone tumours 1 533 6 3.8 1.6 (0.7–3.5) 33.3 21.1 12 (–15 to 39)
Soft-tissue sarcomas 1 995 5 6.0 0.8 (0.4–2.0) 18.1 21.6 –3 (–19 to 12)
Germ-cell tumours 2 124 8 6.0 1.3 (0.7–2.7) 27.9 21.1 7 (–13 to 26)
Carcinomas 3 679 32 18.1 1.8 (1.2–2.5) 54.0 30.6 23 (5 to 42)
Thyroid carcinomas 848 16 4 3.9 (2.4–6.4) 116.1 29.9 86 (29–143)
Other and unspec. cancers 471 1 1.2 0.9 (0.1–6.1) 17.5 20.4 –3 (–37 to 31)




virtually no loss to follow-up and unbiased identification of
population comparisons. However, cancer treatment data
was only available for Danish survivors. Furthermore, com-
plete medical records were available for only 28 of the 43,
mainly because the records of many patients with childhood
cancer diagnosed before 1970 had been destroyed or lost.
As information on patients followed as outpatients were lim-
ited to Denmark and Sweden in the period after 1995, not
all cases of hyperthyroidism were captured. As such under-
registration also applies to the comparison cohort, however,
this is not expected to affect the estimated relative risks. We
only had Danish data on surgical procedures and prescrip-
tions available from 1996. Thus, 4 out of 34 patients with a
hyperthyroidism diagnosis in the hospital register that did
not have prescriptions with any thyroid or anti-thyroid hor-
mones possibly had thyroidectomy before 1996 and there-
fore no need for thyroid medications.
This study demonstrates that treatment of childhood can-
cer may result in the development of hyperthyroidism later
in life. This may be contra intuitive, as cancer treatment
TABLE 2. Observed and expected numbers of first hospital contacts for hyperthyroidism by time since diagnosis of selected cancers.





AER (95% CI)bObserved Expected Observed Expected
ALL 5 568 59 899 16 7.0 2.3 (1.4–3.8) 26.7 11.6 15 (2–28)
1–5 4 734 15 195 2 0.3 6.4 (1.6–25.9) 13.2 2.1 11 (–7 to 29)
6–9 3 580 14 680 4 0.8 5.3 (2.0–14.2) 27.3 5.2 22 (–5 to 49)
10–19 2 909 19 635 6 2.5 2.4 (1.1–5.3) 30.6 12.8 18 (–7 to 42)
≥20 1 647 10 314 4 3.4 1.2 (0.5–3.2) 38.8 32.5 6 (–32 to 44)
Hodgkin lymphoma 2 453 32 324 15 6.3 2.4 (1.4–4.0) 46.4 19.4 27 (3–51)
1–5 1 898 6 455 1 0.6 1.8 (0.3–13.1) 15.5 8.5 7 (–23 to 37)
6–9 1 709 6 941 3 1.0 3.2 (1.0–9.8) 43.2 13.7 30 (–19 to 78)
10–19 1 501 10 045 6 2.2 2.7 (1.2–6.1) 59.7 22.0 38 (–10 to 86)
≥20 900 8 795 5 2.6 2.0 (0.8–4.7) 56.9 29.1 28 (–22 to 78)
CNS tumours 7 922 108 244 30 21.0 1.4 (1.0–2.1) 27.7 19.4 8 (–2 to 18)
1–5 5 957 19 400 9 1.0 9.5 (4.9–18.6) 464 4.9 42 (11–72)
6–9 5 054 20 742 1 1.8 0.6 (0.1–3.9) 4.8 8.8 –4 (–14 to 6)
10–19 4 544 31 731 6 5.6 1.1 (0.5–2.4) 18.9 17.6 1 (–14 to 16)
≥20 3 182 36 129 14 12.7 1.1 (0.7–1.9) 38.8 35.0 4 (–17 to 24)
Thyroid carcinomas 848 13 847 16 4.0 3.9 (2.4–6.4) 115.6 29.8 86 (29–142)
1–5 591 2 076 2 0.3 8.0 (2.0–32.1) 96.3 12.0 84 (–49 to 218)
6–9 595 2 470 2 0.5 4.5 (1.1–18.0) 81.0 18.1 63 (–49 to 175)
10–19 563 4 201 6 1.2 4.8 (2.2–10.8) 142.8 29.6 113 (–1 to 227)
≥20 441 5 034 6 2.2 2.8 (1.2–6.2) 119.2 43.2 76 (–19 to 171)




TABLE 3. Cancer treatment characteristics of 28 Danish survivors with hyperthyroidism.
Haematological cancersa (n) CNS tumours (n) Solid tumoursb (n)
Total
n (%)
Total 5 6 17 28 (100)
Surgery
Yes 2 6 17 25 (89)
Partial thyroidectomy – – 1 1 (4)
Thyroidectomy – – 5 5 (18)
Other 2 6 11 19 (68)
No 3 – – 3 (11)
Radiation
Yesc 4 2 7 13 (46)
Total body irradiation 1 – – 1 (4)
Head and neck 3 2 5 10 (36)
Chest 3 – 2 5 (18)
Other – – 3 3 (11)
No 1 4 10 15 (54)
Chemotherapy
Yes 5 – 3 8 (29)
No – 6 14 20 (71)
Bone marrow transplantation
Yes 1 – – 1 (4)
No 4 6 17 27 (96)
CNS: central nervous system.
aIn the group of haematological cancers, we included leukaemia (n = 1), Hodgkin (n = 3) and non-Hodgkin
lymphoma (n = 1).
bIn the group of solid tumours we included thyroid cancers (n = 6), malignant bone tumours (n = 3), soft tissue
sarcomas (n = 2), neuroblastomas (n = 1), malignant melanomas (n = 1), retinoblastomas (n = 1) and gonadal
germ-cell tumours (n = 2).
cAs some individuals received radiation in multiple areas, the total adds up to more than 13.
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often leads to underactivity of the endocrine system and
especially the thyroid gland. Even though hyperthyroidism is
rare, it can influence the quality of life of a survivor and
cause non-endocrine morbidity if not treated appropriately
[24]. Therefore, it is important that clinicians responsible for
long-term follow-up care of survivors are aware that hyper-
thyroidism may be a late effect following treatment for child-
hood cancer.
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